Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial

Status:	Recruiting
Conditions:	Hepatitis
Therapuetic Areas:	Immunology / Infectious Diseases
Healthy:	No
Age Range:	18 - Any
Updated:	3/16/2015
Start Date:	March 2012
End Date:	February 2018
Contact:	Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:
Email:	Clinical.Trials@bms.com

A Long-Term Follow-Up Study of Subjects Who Participated in a Clinical Trial in Which Peginterferon Lambda-1a (BMS-914143) Was Administered for the Treatment of Chronic Hepatitis C

The primary purpose of this study is to determine whether the hepatitis C virus continues to
remain unable to be detected in subjects who were previously treated with BMS-914143 and
achieved sustained virologic response

Inclusion Criteria:

- Subjects must have received Lambda in a previous trial and have Hepatitis C virus
(HCV) Ribonucleic acid (RNA) < LOQ at the completion of the required post-treatment
follow-up (must enter this study within 6 months of completion of the required
post-treatment follow-up in the previous trial) NOTE: For blinded parent trials,
subjects who have HCV RNA follow-up may enter this study without knowledge of their treatment assignment in the
parent study. Subjects who received control agents (eg, pegylated-interferon alfa) in
the previous protocol will be allowed to participate until unblinded treatment
information is released; at that time subjects will have the option to continue in
the study

Exclusion Criteria:

- Subjects must not have been treated with any antiviral or immunomodulatory drug for
chronic hepatitis C after completion of the previous study of Lambda

We found this trial at

sites

Henry Ford Hospital

2799 W Grand Blvd
Detroit, Michigan 48202

(313) 916-2600